SciSparc Board of Directors to Promote Buyback Program of up to $1 Million
06 juil. 2022 08h30 HE
|
SciSparc Ltd
TEL AVIV, Israel, July 06, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty, clinical-stage pharmaceutical company focusing on the development of...
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
29 juin 2022 08h30 HE
|
SciSparc Ltd
TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
23 juin 2022 09h30 HE
|
SciSparc Ltd
The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
Vyant Bio to Present at the H.C. Wainwright Global Investment Hybrid Conference
19 mai 2022 08h30 HE
|
Vyant Bio, Inc.
Cherry Hill, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021
28 mars 2022 16h30 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex...
VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
24 mars 2022 08h00 HE
|
VistaGen Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused biopharmaceutical company striving to...
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
14 févr. 2022 16h15 HE
|
Vallon Pharmaceuticals Inc.
- Topline data for pivotal abuse study of the Company’s lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with...
VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
10 févr. 2022 16h20 HE
|
VistaGen Therapeutics, Inc.
Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to evaluate PH94B in social anxiety disorder (SAD)...
Central Nervous System Therapeutic Market Size to Hit US$ 209.2 Bn by 2030
08 févr. 2022 10h00 HE
|
Precedence Research
Ottawa, Feb. 08, 2022 (GLOBE NEWSWIRE) -- The global central nervous system therapeutics market size was valued at US$ 113.6 billion in 2020. The rising prevalence of various central nervous system...
Vyant Bio to Present at the H.C. Wainwright Bioconnect Conference
10 janv. 2022 08h00 HE
|
Vyant Bio, Inc.
Cherry Hill, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large...